About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker CYTK · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 4, 2026Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Eje…
NCT06736574 · Heart Failure, Heart Failure With Reduced Ejection Fraction
Omecamtiv Mecarbil (OM), Placebo
CYTK
Cytokinetics
Phase 3Recruiting1,800Sep 2027Registry ↗
Oct 13, 2026Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults…
NCT04848506 · Symptomatic Hypertrophic Cardiomyopathy (HCM)
Aficamten (5 - 20 mg)
CYTK
Cytokinetics
Phase 2/3Enrolling by invitation900Mar 2029Registry ↗
Sep 22, 2026A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptom…
NCT06081894 · Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Aficamten, Placebo
CYTK
Cytokinetics
Phase 3Active, not recruiting500Aug 31, 2026Registry ↗
Aug 27, 2026AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerabil…
NCT06793371 · Symptomatic Heart Failure With Preserved Ejection Fraction…
CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to…
CYTK
Cytokinetics
Phase 2Recruiting60Sep 2026Registry ↗
Aug 18, 2026A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hype…
NCT06412666 · Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopa…
Aficamten, Placebo
CYTK
Cytokinetics
Phase 2/3Active, not recruiting65Jan 2030Registry ↗
Jun 9, 2026Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in…
NCT05767346 · Obstructive Hypertrophic Cardiomyopathy (oHCM)
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Plac…
CYTK
Cytokinetics
Phase 3Completed175Feb 28, 2025Registry ↗
Mar 3, 2026Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With S…
NCT05186818 · Obstructive Hypertrophic Cardiomyopathy (oHCM)
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match…
CYTK
Cytokinetics
Phase 3Completed282Nov 10, 2023Registry ↗
Feb 24, 2026Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of…
NCT04219826 · Hypertrophic Cardiomyopathy (HCM)
CK-3773274 (5 - 15 mg), CK-3773274 (10 - 30 mg)
CYTK
Cytokinetics
Phase 2Completed96Feb 28, 2023Registry ↗
May 1, 2025A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants
NCT05877053 · Healthy Participants
CK-4021586, Placebo for CK-4021586
CYTK
Cytokinetics
Phase 1Completed102Nov 20, 2024Registry ↗
Mar 30, 2025Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
NCT04175808 · QT Intervals Changes, QTc Intervals Changes
Omecamtiv Mecarbil (OM), Placebo
CYTK
Cytokinetics
Phase 1Completed70Mar 4, 2020Registry ↗
Jan 24, 2025A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects
NCT03767855 · Symptomatic Obstructive Hypertrophic Cardiomyopathy, Health…
CK-3773274 - Granules in Capsule, Placebo - Granules in Cap…
CYTK
Cytokinetics
Phase 1Completed114Jan 3, 2020Registry ↗
Dec 5, 2024A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Scl…
NCT04944784 · Amyotrophic Lateral Sclerosis
Reldesemtiv, Placebo
CYTK
Cytokinetics
Phase 3Terminated489Jul 18, 2023Registry ↗
Oct 17, 2024A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants
NCT05662215 · Healthy Participants
CK-3828136, Placebo for CK-3828136
CYTK
Cytokinetics
Phase 1Terminated57Aug 8, 2023Registry ↗
Aug 13, 2024A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
NCT05442775 · Amyotrophic Lateral Sclerosis
Reldesemtiv
CYTK
Cytokinetics
Phase 3Terminated71Jun 7, 2023Registry ↗
Dec 19, 2023Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
NCT05924815 · Healthy Participants
Aficamten, Aficamten-matching Placebo
CYTK
Cytokinetics
Phase 1Completed44Nov 14, 2023Registry ↗
Mar 7, 2023Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
NCT03759392 · Heart Failure With Reduced Ejection Fraction
Omecamtiv Mecarbil, Placebo
CYTK
Cytokinetics
Phase 3Completed276Nov 8, 2021Registry ↗
Nov 5, 2021Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced…
NCT02929329 · Heart Failure
Omecamtiv Mecarbil, Placebo
CYTK
Cytokinetics
Phase 3Completed8,256Sep 14, 2020Registry ↗
Aug 12, 2021COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure
NCT01786512 · Modified Release Oral Formulation, Left Ventricular Systoli…
Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbi…
CYTK
Cytokinetics
Phase 2Completed544Jul 22, 2015Registry ↗
Jul 30, 2021Omecamtiv Mecarbil Post-trial Access Study
NCT04464525 · Chronic Heart Failure With Reduced Ejection Fraction
Omecamtiv mecarbil
CYTK
Cytokinetics
Phase 3Withdrawn0Nov 27, 2026Registry ↗
Jul 30, 2021Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal In…
NCT01737866 · Heart Failure
AMG 423
CYTK
Cytokinetics
Phase 1Completed13Jan 2013Registry ↗
Jul 30, 2021Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients
NCT01077167 · Heart Failure
Omecamtiv mecarbil
CYTK
Cytokinetics
Phase 2Withdrawn0May 2011Registry ↗
Jul 27, 2021Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced…
NCT02695420 · Heart Failure With Reduced Ejection Fraction
25 mg Omecamtiv Mecarbil, Placebo
CYTK
Cytokinetics
Phase 2Completed81Apr 6, 2017Registry ↗
Jul 27, 2021Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults
NCT02601001 · Healthy Volunteer
Omecamtiv mecarbil, Placebo
CYTK
Cytokinetics
Phase 1Completed50Jan 6, 2016Registry ↗
Jul 27, 2021Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subje…
NCT01300013 · Heart Failure
Placebo, Omecamtiv mecarbil
CYTK
Cytokinetics
Phase 2Completed614Apr 2013Registry ↗
Jun 15, 2021A Study for Patients Who Completed VITALITY-ALS (CY 4031)
NCT02936635 · Amyotrophic Lateral Sclerosis (ALS)
tirasemtiv
CYTK
Cytokinetics
Phase 3Completed280Oct 26, 2018Registry ↗
May 14, 2021A Study of CK-1827452 Infusion in Stable Heart Failure
NCT00624442 · Heart Failure
CK-1827452, CK-1827452
CYTK
Cytokinetics
Phase 2Completed45Feb 2009Registry ↗
Sep 11, 2020A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic La…
NCT03160898 · Amyotrophic Lateral Sclerosis
Reldesemtiv, Placebo
CYTK
Cytokinetics
Phase 2Completed458Mar 7, 2019Registry ↗
Sep 9, 2020Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for…
NCT02496767 · Amyotrophic Lateral Sclerosis
Tirasemtiv, Placebo tablets
CYTK
Cytokinetics
Phase 3Completed744Mar 9, 2017Registry ↗
Aug 31, 2020A Study of CK-2127107 in Patients With Spinal Muscular Atrophy
NCT02644668 · Spinal Muscular Atrophy
Placebo, Reldesemtiv 150 mg
CYTK
Cytokinetics
Phase 2Completed70May 31, 2018Registry ↗
Mar 31, 2020Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
NCT01709149 · Amyotrophic Lateral Sclerosis
CK-2017357, Placebo tablets
CYTK
Cytokinetics
Phase 2Completed711Mar 2014Registry ↗
Jan 21, 2020Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency
NCT00748579 · Heart Failure
CK-1827452, CK-1827452
CYTK
Cytokinetics
Phase 2Terminated2Nov 2008Registry ↗
Jan 13, 2020A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma
NCT00343564 · Non-Hodgkin's Lymphoma, Hodgkin's Disease
SB-743921, SB-743921
CYTK
Cytokinetics
Phase 1/2Completed68Jul 2010Registry ↗
Sep 24, 2019Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
NCT01268280 · Myasthenia Gravis
Placebo, 250 mg CK-2017357
CYTK
Cytokinetics
Phase 2Terminated32Oct 2012Registry ↗
May 14, 2019A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication
NCT01131013 · Intermittent Claudication, Peripheral Artery Disease
Placebo, 375 mg CK-2017357
CYTK
Cytokinetics
Phase 2Completed61Mar 2011Registry ↗
May 10, 2019A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01089010 · Amyotrophic Lateral Sclerosis
Placebo, 250 mg CK-2017357
CYTK
Cytokinetics
Phase 2Completed67Nov 2010Registry ↗
May 7, 2019A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Latera…
NCT01378676 · Amyotrophic Lateral Sclerosis
Placebo (Part A), CK-2017357 (Part A)
CYTK
Cytokinetics
Phase 2Completed49Mar 2012Registry ↗
May 6, 2019A Study of Ispinesib in Metastatic Breast Cancer
NCT00607841 · Breast Neoplasms
Ispinesib, Ispinesib
CYTK
Cytokinetics
Phase 1Terminated16Nov 2009Registry ↗
May 3, 2019Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral…
NCT01486849 · Amyotrophic Lateral Sclerosis
CK-2017357, Placebo
CYTK
Cytokinetics
Phase 2Completed27Mar 2012Registry ↗
Aug 21, 2018PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina
NCT00682565 · Heart Failure, Myocardial Ischemia
CK-1827452 24mg and 6 mg iv infusion, CK-1827452 12.5mg cap…
CYTK
Cytokinetics
Phase 2Completed94Nov 2008Registry ↗
Oct 14, 2015A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers
NCT01380223 · Heart Failure
placebo, omecamtiv mecarbil
CYTK
Cytokinetics
Phase 1Completed35Apr 2006Registry ↗

40 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:34 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances